Skip to main content
Top
Published in: International Journal of Colorectal Disease 2/2020

01-02-2020 | Metastasis | Original Article

Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study

Authors: Yizhi Ge, Shijun Lei, Bo Cai, Xiang Gao, Guobin Wang, Lin Wang, Zheng Wang

Published in: International Journal of Colorectal Disease | Issue 2/2020

Login to get access

Abstract

Purpose

It is unclear how primary tumor location affects the pulmonary metastasis in colorectal cancer patients with different primary tumor locations. We aim to explore the relationship between primary tumor location and the incidence and prognosis of colorectal cancer patients with pulmonary metastasis at diagnosis.

Methods

From Surveillance, Epidemiology, and End Results (SEER) database, 9920 out of 192,969 CRC patients were identified with pulmonary metastasis at diagnosis between 2010 and 2015. Patients were classified into three subsets according to primary tumor location. The incidence of pulmonary metastasis and median survival were calculated. Multivariable logistic and Cox regression were performed to identify the risk factors of pulmonary metastasis and prognosis.

Results

The incidence of pulmonary metastasis was 5.14% in the entire colorectal cancer cohort and 25.66% in metastatic colorectal cancer patients. The median survival of those patients was 10 months. Rectal cancer patients exhibited the highest incidence of pulmonary metastasis, while they had the longest median survival (15 months). The right-sided colon cancer patients had the lowest incidence of pulmonary metastasis, but the shortest median survival (8 months). 61 to 80 years old, over 80, black, two or three extrapulmonary metastatic sites and CEA-positive had a negative influence both on the incidence and prognosis.

Conclusions

The importance of primary tumor location in affecting the incidence of pulmonary metastasis and prognosis of colorectal cancer patients was highlighted in this study. Primary tumor location should be considered in clinical interference and personalized treatment for colorectal cancer patients with pulmonary metastasis.
Appendix
Available only for authorised users
Literature
3.
go back to reference Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, Matsuguma H, Ikeda N, Yoshino I, Ozeki Y, Takagi K, Goya T, Kawamura M, Hamada C, Kobayashi K (2013) Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257(6):1059–1064. https://doi.org/10.1097/SLA.0b013e31826eda3b CrossRefPubMed Iida T, Nomori H, Shiba M, Nakajima J, Okumura S, Horio H, Matsuguma H, Ikeda N, Yoshino I, Ozeki Y, Takagi K, Goya T, Kawamura M, Hamada C, Kobayashi K (2013) Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann Surg 257(6):1059–1064. https://​doi.​org/​10.​1097/​SLA.​0b013e31826eda3b​ CrossRefPubMed
9.
go back to reference Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Zakelj M, Zadnik V, Becker N, Hackert T, Magi M, Cassetti T, Sassatelli R, Grutzmann R, Merkel S, Goncalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Buchler MW, Schrotz-King P, Brenner H (2017) Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. https://doi.org/10.1136/gutjnl-2017-314828 CrossRefPubMed Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Zakelj M, Zadnik V, Becker N, Hackert T, Magi M, Cassetti T, Sassatelli R, Grutzmann R, Merkel S, Goncalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Buchler MW, Schrotz-King P, Brenner H (2017) Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. https://​doi.​org/​10.​1136/​gutjnl-2017-314828 CrossRefPubMed
11.
go back to reference Surveillance, Epidemiology, and End Results. Overview of the SEER Program. National Cancer Institute (https://seercancergov/about/overviewhtml. Accessed April 2018 Surveillance, Epidemiology, and End Results. Overview of the SEER Program. National Cancer Institute (https://​seercancergov/​about/​overviewhtml.​ Accessed April 2018
13.
go back to reference Bufill JA (1990) Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Annals of internal medicine 113(10):779–788CrossRefPubMed Bufill JA (1990) Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Annals of internal medicine 113(10):779–788CrossRefPubMed
16.
go back to reference Venook A, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil B (2016) Impact of primary tumor location on overall survival and progression free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34 (Suppl. abstr 3504): 3504-3504 Venook A, Niedzwiecki D, Innocenti F, Fruth B, Greene C, O’Neil B (2016) Impact of primary tumor location on overall survival and progression free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34 (Suppl. abstr 3504): 3504-3504
18.
go back to reference Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A (2018) Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdy140 CrossRefPubMed Cremolini C, Antoniotti C, Lonardi S, Bergamo F, Cortesi E, Tomasello G, Moretto R, Ronzoni M, Racca P, Loupakis F, Zaniboni A, Tonini G, Buonadonna A, Marmorino F, Allegrini G, Granetto C, Masi G, Zagonel V, Sensi E, Fontanini G, Boni L, Falcone A (2018) Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Ann Oncol. https://​doi.​org/​10.​1093/​annonc/​mdy140 CrossRefPubMed
26.
go back to reference Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S (2014) Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25(10):1995–2001. https://doi.org/10.1093/annonc/mdu275 CrossRefPubMed Missiaglia E, Jacobs B, D’Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S (2014) Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25(10):1995–2001. https://​doi.​org/​10.​1093/​annonc/​mdu275 CrossRefPubMed
28.
go back to reference Wong HL, Lee B, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P (2016) Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer 15(2):e9–e15. https://doi.org/10.1016/j.clcc.2016.02.007 CrossRefPubMed Wong HL, Lee B, Field K, Lomax A, Tacey M, Shapiro J, McKendrick J, Zimet A, Yip D, Nott L, Jennens R, Richardson G, Tie J, Kosmider S, Parente P, Lim L, Cooray P, Tran B, Desai J, Wong R, Gibbs P (2016) Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer 15(2):e9–e15. https://​doi.​org/​10.​1016/​j.​clcc.​2016.​02.​007 CrossRefPubMed
36.
go back to reference Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28(8):1713–1729. https://doi.org/10.1093/annonc/mdx175 CrossRefPubMedPubMedCentral Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, Cervantes A, Ciardiello F (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28(8):1713–1729. https://​doi.​org/​10.​1093/​annonc/​mdx175 CrossRefPubMedPubMedCentral
Metadata
Title
Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study
Authors
Yizhi Ge
Shijun Lei
Bo Cai
Xiang Gao
Guobin Wang
Lin Wang
Zheng Wang
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
International Journal of Colorectal Disease / Issue 2/2020
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-019-03434-8

Other articles of this Issue 2/2020

International Journal of Colorectal Disease 2/2020 Go to the issue